FDA Warning Letter: Indiana Chem-Port (2022)

In short: FDA issued amended Warning Letter 320-22-11 to Indiana Chem-Port on 2 February 2022 after an August 2021 inspection of its API manufacturing facility in Vadodara, India. The letter cited equipment, process validation, cleaning, stability, quality-unit, data-integrity and U.S. registration/listing concerns.

This article summarizes the agency’s observations and response requests as described in the FDA warning letter. It is a historical account of the amended letter, not a determination of the firm’s present compliance status.

Inspection and letter timeline

FDA’s Center for Drug Evaluation and Research inspected Indiana Chem-Port from 2 to 7 August 2021. The agency acknowledged the firm’s 15 October 2021 response to its Form FDA 483, then issued amended Warning Letter 320-22-11 on 2 February 2022. The letter described significant deviations from current good manufacturing practice for active pharmaceutical ingredients (APIs) and requested a written response within 15 working days of receipt (FDA Warning Letter 320-22-11, amended 2 February 2022).

Main findings described by FDA

The warning letter identified five principal quality-system areas:

1. Equipment condition and qualification: FDA described rust-like residue on product-contact surfaces, improvised repairs and damaged equipment. It also said the firm lacked adequate qualification procedures for manufacturing and QC laboratory equipment.
2. Process validation and change control: FDA said the API manufacturing process had not been validated and that process changes had been made without adequate justification or change control.
3. Cleaning procedures and validation: FDA reported that cleaning procedures for shared equipment were missing or inadequate, that operators described cleaning without following written procedures, and that the cleaning process had not been sufficiently validated to support cross-contamination control.
4. Stability and supporting records: FDA said the firm’s stability programme and protocols were inadequate. The letter questioned a retest date based on reserve samples from one older batch stored in an area without humidity control and noted that manufacturing records for the batch had been destroyed while the API remained in U.S. distribution.
5. Quality-unit oversight and data integrity: FDA cited missing pages in a manufacturing logbook, incomplete batch records in an unofficial laboratory, and destruction of batch and reserve-sample records. It said the quality unit lacked sufficient authority and oversight to ensure reliable operations and data.

The letter also raised alleged U.S. establishment-registration and drug-listing violations. In that 2022 letter, FDA cited section 510(i)(1) and section 502(o) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§360(i)(1) and 352(o), and 21 CFR §§207.17 and 207.41, and said the alleged omissions could render the products misbranded. These are the agency’s findings and legal position stated in Warning Letter 320-22-11, not a new assessment of the firm’s current status.

Corrective-action themes requested by FDA

FDA requested a broad corrective and preventive action (CAPA) response. The requests covered equipment and facility oversight, process validation across the product lifecycle, evaluation of process changes, cleaning validation and a retrospective cross-contamination assessment, a scientifically supported stability programme, and stronger quality-unit authority and documentation controls. The agency also asked for an investigation into the scope and root causes of data-integrity problems, a risk assessment for affected U.S.-distributed products, and a management-level remediation plan (FDA Warning Letter 320-22-11, amended 2 February 2022).

The letter referenced FDA guidance on process validation and data integrity and FDA’s API GMP guidance based on ICH Q7. It recommended a qualified consultant while stating that responsibility for compliance remained with firm management. The warning letter does not publish the firm’s subsequent corrective-action response or establish whether FDA later accepted it.

Import-alert status

The warning letter records that FDA placed Indiana Chem-Port on Import Alert 66-40 on 13 December 2021. The currently posted FDA Import Alert 66-40 was published on 1 October 2026 and still lists Indiana Chem-Port in multiple product categories, with the listed entries dated 13 December 2021 and 26 May 2022. Check the live alert before relying on an import-status statement, because FDA may revise the listing.

Record-retention context

For batch-associated finished-drug records, retain records at least one year after the expiry date of the respective product batch. EU batch documentation must be kept for one year after batch expiry or at least five years after Qualified Person certification, whichever is longer (EudraLex Volume 4, Part I, Chapter 4 §4.11, revision 1, 2011). The corresponding U.S. finished-drug rule is 21 CFR §211.180(a), current eCFR text (2026), which generally requires at least one year after batch expiry, with a different period for certain OTC products without expiry dating. Apply any longer local-law or marketing-authorisation period. API-specific record retention may also depend on applicable rules and agreements for the markets served.

Related guidance

• Process validation in pharmaceutical industry
• SOP on cleaning validation
• SOP on data integrity

References

1. U.S. Food and Drug Administration. Indiana Chem-Port, MARCS-CMS 618173, Warning Letter 320-22-11 (amended 2 February 2022). Official FDA warning letter.
2. U.S. Food and Drug Administration. Import Alert 66-40: Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs (current page published 1 October 2026). Official FDA Import Alert.
3. European Commission. EudraLex, Volume 4, Part I, Chapter 4: Documentation, revision 1 (January 2011; effective 30 June 2011), §4.11. Official PDF.
4. United States. 21 CFR §211.180(a), current eCFR text (2026). Official eCFR.